Although those inflammatory symptoms are, at least partially, improved by treatment with a JAK1/2 inhibitor (16, 20), the molecular mechanisms by which these inflammatory responses are induced and which molecules are key in the initiation or progression of inflammation in patients with PRAAS are unknown. Here, JAK1 is linked to proteosome-associated autoinflammatory syndrome.